B
BVF Partners L.P.
+ HoldingFDMT
+16.11%
3M Return
$14.110
-0.539 (-3.82%)At close
Loading chart…
- High
- 14.600
- Open
- 14.490
- VWAP
- 14.12
- Vol
- 1.40M
- Mkt Cap
- 1.08B
- Low
- 13.665
- Amount
- 19.83M
- EV/EBITDA, TTM
- 1.44
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Valuation Metrics
The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT) is -1.26, compared to its 5-year average forward P/E of -4.89.
Whales holding FDMT
Events Timeline
News
2.008-18stocktwitsOCUL and FDMT Stocks Surge on EyePoint Trial Setback
8.507-24NASDAQ.COMBiotech Sector Highlights: Regulatory Approvals and Restructuring
9.007-20seekingalpha4D Molecular Therapeutics Releases Positive Two-Year Data for AMD Candidate 4D-150
9.007-20NASDAQ.COM4D Molecular Therapeutics Reports Positive 2-Year PRISM Trial Data
9.007-18NewsfilterPositive Two-Year Data for 4D-150 in Wet AMD Clinical Trial
FDMT FAQ — answered by Alphio AI
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.